News for Emergent BioSolutions Inc. (0IGA.L)

**media[646568]**

On May 13, 2025, Joseph Papa, President and Chief Executive Officer of Emergent BioSolutions Inc (EBS), purchased 60,000 shares of the company, as reported in t

GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (: EBS) announced today that members of its executive management team will part

Emergent BioSolutions (EBS) is set to participate in several major investor conferences in May and June 2025. Key conferences include the RBC Global Hea

Texas-based Asset Entities Inc. (ASST) is up over 54 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

The following slide deck was published by Emergent BioSolutions Inc.

Emergent BioSolutions Inc. (NYSE:EBS) Q1 2025 Earnings Call May 7, 2025 5:00 PM ETCompany ParticipantsFrank Vargo - Vice President, Assistant TreasurerJoe...

**media[618037]**

Emergent BioSolutions (EBS) signs a $65 million contract with Ontario Ministry of Health for NARCAN® Nasal Spray supply. The agreement supports a 30% decre

Here is a list of companies that announced the most significant buybacks as a percentage of their market caps.

Emergent BioSolutions struggles with declining revenues, rising competition, and weak growth prospects. Read why I rate EBS stock as a sell.

GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (:EBS), a leading public health company that delivers protective and life-sav

**media[572510]**

Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada LONDON and

**media[571897,571898]**

Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada

Despite announcing the completion of its first biologics site acquisition in the US, Syngene, the contract research arm of Biocon, saw its shares dip 0.42% at Rs 703.10 on the BSE as of 10:35 AM in intraday trading.

GAITHERSBURG, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (:EBS) today announced that it has completed the sale of its Baltimore-Bayvie

GAITHERSBURG, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (: EBS) today announced it has recently secured approximately $27 million in